Eldaly Abdullah S, Avila Francisco R, Torres-Guzman Ricardo A, Maita Karla C, Garcia John P, Serrano Luiza P, Saleem Humza Y, Forte Antonio J
Division of Plastic Surgery, Mayo Clinic, Jacksonville, Florida, United States.
Department of General Surgery, Mayo Clinic, Jacksonville, Florida, United States.
J Clin Transl Res. 2022 May 25;8(3):243-255. eCollection 2022 Jun 29.
Lymph node transfer surgery (LNTS) is indicated in secondary lymphedema (LE) patients who do not respond to conservative therapy. Animal models are the spearhead of LE research and were used to pioneer most of the surgical interventions currently in practice. We conducted a systematic review of the literature to explore animal models dedicated to LNTS to compare different species, techniques, and outcomes.
Four databases were searched: PubMed, Cumulative Index of Nursing and Allied Health Literature, Scopus, and Web of Science. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis as our basis of organization.
Avascular lymph node graft (ALNG) and vascularized lymph node transfer (VLNT) effectively treated LE and lead to better outcomes than controls. Whole ALNGs are superior to fragmented ALNGs. Larger fragments are more likely to be reintegrated into the lymphatic system than small fragments. VLNT was superior to whole and fragmented ALNG. Increasing the number of VLNT resulted in better outcomes. Adipose-derived stem cells improved outcomes of VLNT; vascular endothelial growth factor C and D and platelet-rich plasma improved outcomes for ALNG. Cryopreservation of lymph nodes (LNs) did not affect outcomes for ALNG. The critical ischemia and venous occlusion time for LN flaps were 4-5 and 4 h, respectively. The critical time for reperfusion injury was 2 h. Some of the novel models included venous LNT, and cervical adipocutaneous flap to groin.
Current evidence from animals favors VLNT over other surgical interventions. Several pharmacological therapies significantly improved outcomes of ALNG and VLNT.
LE is a chronic condition affecting millions of patients worldwide. LNTS is becoming more popular as a LE treatment. Animal models have led the LE research for decades and developing new models for LE are essential for LE research. This systematic review aims to summarize the existing animal models dedicated to LNTS. We believe that this review is critical to guide researchers in the selection of the model that is best fit for their hypothesis-driven experiments.
淋巴结转移手术(LNTS)适用于对保守治疗无反应的继发性淋巴水肿(LE)患者。动物模型是LE研究的前沿领域,目前实践中大多数手术干预都是率先在动物模型上开展的。我们对文献进行了系统综述,以探索专门用于LNTS的动物模型,比较不同物种、技术和结果。
检索了四个数据库:PubMed、护理及相关健康文献累积索引、Scopus和科学网。我们使用系统评价和Meta分析的首选报告项目作为组织依据。
无血管淋巴结移植(ALNG)和带血管蒂淋巴结转移(VLNT)能有效治疗LE,且比对照组效果更好。完整的ALNG优于碎片化的ALNG。较大的碎片比较小的碎片更有可能重新整合到淋巴系统中。VLNT优于完整和碎片化的ALNG。增加VLNT的数量可带来更好的结果。脂肪来源干细胞改善了VLNT的效果;血管内皮生长因子C和D以及富血小板血浆改善了ALNG的效果。淋巴结冷冻保存不影响ALNG的结果。淋巴结皮瓣的临界缺血时间和静脉阻断时间分别为4 - 5小时和4小时。再灌注损伤的临界时间为2小时。一些新型模型包括静脉LNT以及从颈部脂肪皮瓣转移至腹股沟。
目前来自动物研究的证据表明,VLNT比其他手术干预更具优势。几种药物治疗显著改善了ALNG和VLNT的效果。
LE是一种影响全球数百万患者的慢性疾病。LNTS作为一种LE治疗方法正变得越来越流行。几十年来,动物模型一直引领着LE研究,开发新的LE模型对LE研究至关重要。本系统综述旨在总结现有的专门用于LNTS的动物模型。我们认为,这篇综述对于指导研究人员选择最适合其假设驱动实验的模型至关重要。